SBIR Phase I: Anti-infective Foley catheters for long-term prevention of catheter-associated urinary tract infections

这项小企业创新研究（SBIR）第一阶段项目的更广泛影响/商业潜力是一种新型抗感染涂层，以减轻导尿管相关性尿路感染（CAUTIs）。这些感染通常会导致严重的并发症，估计每年导致13,000人死亡，同时导致美国医疗保健系统直接和间接成本近62亿美元。混合导管技术旨在提供持续的保护，防止由生物膜引起的感染，通过生物膜排斥和静态抗菌表面部分的协同组合，提供慢性抗菌和生物膜排斥特性。所提出的导管技术旨在证明显着降低感染率，提高导管寿命，以及对病原体的广谱保护，以降低与长期导管使用相关的感染风险，减少患者对抗生素的依赖。这项技术的应用范围具有更广泛的潜力，超出了导尿管的应用范围，包括其他基于导尿管的应用和急性住院医疗设备。总体技术目标是改善感染控制实践和风险降低许多常见的美国医院内程序。这个小企业创新研究（SBIR）一期项目旨在开发一种具有增强抗病原体和生物膜抗性的新型设备表面涂层。目的是开发和验证一种创新的导管设计，提供对生物膜形成的长期抵抗，优于当前的单模态方法。在这个一期项目中，两性离子部分的抗生物膜特性将与双离子部分持久的静态杀微生物作用结合在一起，形成一个单一的涂层。在材料水平上的初步台架试验表明，与目前可用的方法相比，显著减少了生物膜的形成。将完成对新型复合模式材料的体外测试，以证明与现有的抗菌Foley导管相比，感染风险降低。然后，这种专有材料将被整合到制造过程中，以防止在使用导管的医疗环境中感染。该奖项反映了美国国家科学基金会的法定使命，并通过使用基金会的知识价值和更广泛的影响审查标准进行评估，被认为值得支持。

The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project is a novel anti-infective coating to mitigate catheter-associated urinary tract infections (CAUTIs). These infections often lead to severe complications, resulting in an estimated 13,000 annual deaths while incurring nearly $6.2 billion in direct and indirect U.S. healthcare system costs. The hybrid catheter technology aims to provide continuous protection against infections caused by biofilms, offering chronic antimicrobial and biofilm-repelling properties through a synergistic combination of biofilm-repelling and static antimicrobial surface moieties. The proposed catheter technology aims to demonstrate significant decreases in infection rates, improved catheter longevity, and broad-spectrum protection against pathogens to reduce the risks of infection associated with long-term catheter use, reducing the reliance of patients on antibiotics. The scope of this technology's application has broader potential beyond urinary catheters to include other catheter-based applications and acute in-hospital use medical devices. The overall technological objectives are to improve infection control practices and risk reduction for many common U.S. in-hospital procedures.This Small Business Innovation Research (SBIR) Phase I project aims to develop a novel device surface coating with enhanced anti-pathogen and biofilm resistance. The objective is to develop and validate in vitro an innovative catheter design that offers prolonged resistance to biofilm formation, superior to current single modality approaches. During this Phase 1 project, the anti-biofilm properties of zwitterionic moieties will be combined with the durable static microbicidal action of a Gemini-dicationic moieties into a single coating. Initial bench tests at the materials level demonstrate a significant reduction in biofilm formation superior to currently available methods. Invitro testing will be completed on the novel combined mode material to demonstrate reduced infection risks relative to existing antimicrobial Foley catheters. The proprietary material will then be integrated into manufacturing processes to prevent infection in catheter-use medical settings.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.